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IN THE NEWS
DRUG SHORTAGES: FDASIA AND INCENTIVES FOR
COMPLIANCE THROUGH THE TAX CODE
RobertAlinsky*
I. INTRODUCTION
The Food and Drug Administration Safety and
Innovation Act (FDASIA) became law in July 2012
and authorizes the Federal Drug Administration
(FDA) to take more aggressive action in combating
drug shortages in the U.S.' FDASIA provides the
FDA with new tools to better prepare for impending
shortages such as more strict reporting requirements
for pharmaceutical companies engaged in the
manufacture of certain covered drugs.2 However,
while an alert system is important, the new law
does not directly address the underlying issue of
how to prevent drug shortages by ensuring an
adequate supply.' As many public, private, and
governmental organizations stress, drug shortages
is a pressing issue affecting many people who rely
on critical medications. This issue needs immediate
aggressive legislative attention.4 The FDA is seeking
solutions to this problem and is open to working with
pharmaceutical companies to increase production
of certain drugs.5 In addition to the existing early
warning system, one possible solution would be
to use the tax code to create positive incentives for
drug manufacturers to prevent and relieve drug
shortages. This article argues to broaden the scope
of the Increasing Research Activities Credit to cover
pharmaceutical company expenses targeted at drug
shortages, and that the calculation of the credit could
be based on the formula employed in the Renewable
Energy Production Credit.6
II. BACKGROUND
Under FDASIA's broad-stroke policy objectives
aimed at reducing drug shortages, the FDA is
required to establish a Drug Shortages Task Force
(Task Force) whose responsibility is to develop and
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implement a drug shortages plan. 7 The Task Force
has since opened its plan development to public
comments and has articulated a number of areas in
which they seek specific suggestions.8 One such item
the Task Force seeks comments on are "incentives
that FDA can provide to encourage manufacturers to
establish and maintain high-quality manufacturing
practices, to develop redundancy in manufacturing
operations, to expand capacity, and/or to create
other conditions to prevent or mitigate shortages."9
The tax system can be utilized for such incentive
behavior.o One available avenue is to employ the
current Increased Research Activities credit and
incorporate into that credit the formula used in the
highly successful Energy Production Credit for
renewable fuels.
A. FDASIA
Congress updated The Federal Food, Drug &
Cosmetic Act (FD&C Act) through FDASIA by
amending certain provisions which now require
pharmaceutical companies to notify the FDA of
impending shortages and to keep records of drug
levels.' 1 The FDA was further instructed to facilitate
better inter- and intra-agency communication
about drug shortages and use a Task Force to form
a strategic plan to thwart shortages.12 The Task
Force seeks solutions to attack the underlying
problems of drug shortages including encouraging
increased manufacturing, exploring better metrics
for monitoring drug levels, and incentivizing
pharmaceutical companies to "establish and
maintain high-quality manufacturing practices, to
develop redundancy in manufacturing operations, to
expand capacity, and/or to create other conditions to
prevent or mitigate shortages." 3
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B. Increased Research Credit
Under 26 U.S.C. § 41, the tax code provides
corporations with a non-refundable incremental
tax credit for increased qualified research expenses
and activities. 14 The credit is limited to certain
activities outlined in a four-part test, requiring:
expenses that qualify as research under 26
USC § 174; technological in nature; involves a
business component; and involves a process of
experimentation related to a qualified purpose.15 To
satisfy the business component element, expenses
must be related to research regarding products,
process, formulas, or software, which are to be held
for sale, lease, or used in the organization's trade or
business.' 6 The purposes for which the credit is to
be applied are limited to those related to a new or
improved function, performance, or reliability and
quality. 17 Permitted purposes do not include, among
other things, research after commercial production
has begun, adapting a business component to a
particular customer's needs, or duplication of an
existing business component. 18 Seemingly narrow,
the code could be broadened by interpreting what
the permitted purposes apply to and should be read
to mean.19
C. Renewable Energy Production Credit
Intended to incentivize production of alterative
energy sources to fossil fuels, the Renewable
Energy Production Credit permits a tax credit to
production facilities that produce electricity from
renewable sources.2" The credit is calculated by a
simple mathematical formula based on the amount
of electricity actually produced by the qualified
facility.2' This tax credit has successfully incentivized
the use of alternative fuels to produce electricity, and
the production-dependent formula used to calculate
the credit is directly related to increased production
of electricity by renewable energy.22
III. ANALYSIS
The Task Force's recent comment period sought
suggestions from the public to help relieve drug
shortages. Notably, the Task Force announced that
it is looking for ways to work with other federal
government agencies to accomplish its mission. 23
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The Treasury Department can provide a resource to
the FDA in this regard by promulgating regulations or
pressuring congress for a bill that would incentivize
pharmaceutical companies to maintain sufficient
quantities, more effectively monitor drug levels,
and/or resume manufacturing of drugs that the FDA
determines are in shortage.24 Sections 41 and 45
of the tax code could be used together to promote
synergy between pharmaceutical companies and
the FDA to improve manufacturing mechanisms,
processes, and supply monitoring systems of the
critical drugs needed by many Americans.
A. Reinterpret § 41 to Accommodate FDASIA
Objectives
Faster and more efficient then asking Congress to
pass a bill granting new authority to Treasury or
the FDA, the Task Force should work with Treasury
to draft new interpretive, legislative, or procedural
regulations to expand the scope of the Increasing
Research Credit to include stop-gap drug shortage
efforts by drug companies. The new regulation
should interpret the qualified research language in
§ 41 to include such measures that allow a company
to easily and quickly produce more of an essential
drug.25 Moreover, the regulation's authority is linked
to the policy objectives of Congress, which support
incentivizing the pharmaceutical industry through
tax credits.26 The statute is intended to incentivize
research activities, and such activities will benefit
society if they include pharmaceutical efforts to
increase production of drugs that are facing a critical
level of supply as prescribed by the FDA. 27
Although the credit is limited to certain purposes,
the current language of the credit encompasses the
type of costs associated with activities outlined in
FDASIA objectives. 28 Funds spent towards meeting
FDASIA's goal of research and implementation of
new processes to prevent shortages and maintain
adequate drug supplies meet the requirements
of § 41: expenditures made in discovering new
technological information relating to a new or
improved function, performance, or reliability or
quality of a business component. 29 The language of
the statute is broad enough to encompass the intent
of FDASIA by allowing a credit for pharmaceutical
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companies who invest funds in better tools and new
methods in order to improve their ability to prevent
shortages and continue or restart manufacturing
when the FDA alerts that supplies are low.30
However, Treasury should work with the Task
Force to develop language that reinterprets the
scope of the credit to cover broader costs associated
with developing systems to better monitor drug
stockpiles for the enumerated drugs listed by FDA.
Additionally, a Treasury regulation could better
explain the "reliability" function of permitted
purposes of § 41(d)(3)(iii) to account for expenses
used to increase reliability of drug manufacturing
practices. This would encourage production of
better quality products, which would increase
overall drug stock and reduce costs associated
with defective drug units.31 A regulation could also
interpret § 41 and associated treasury regulations to
limit the disallowed purposes of products already
manufactured or duplication of business competent
by outright excluding such research activities
pertaining to drug shortages. 32
B. Incorporate the Renewable Energy
Production Credit Formula
To further achieve the goals of the FDASIA
Task Force, a treasury regulation should further
interpret and adjust procedurally how the credit
will be calculated based on the methodology used
in calculating the Energy Production Credit.33 As
discussed, this credit amount is based upon the
amount of energy produced by alternative fuel
facilities. Renewable Energy Production Credit
could be applied in such a way that pharmaceutical
producers would receive a tax credit to offset the costs
incurred by efforts to improve production processes
to prevent or alleviate a shortage. The formula
will provide credits proportional to the additional
drug units produced due to improved processes.
By integrating the Renewable Energy Production
Credit formula, pharmaceutical companies will
only get the credit if their research and productive
activities directly contribute to increased levels of
critical pharmaceuticals. This measure will help
to reduce over-production for the sole benefit of
receiving the credit. Moreover, the regulation should
specify that only expenses related to drugs named
on FDA shortage lists could qualify for the credit;
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allocation of mixed-use research expenses would
be permitted.34 Therefore, the credit benefit will
be allowed based on the costs actually spent for
investment in solving or preventing a drug shortage.
IV. CONCLUSION
Drug Shortages present a serious problem and
there is an ever-increasing need for more regulatory
adjustments to better combat the issue.35 In an effort
to encourage the pharmaceutical industry to work
with the FDA to prevent and alleviate drug shortages
under the newly invigorated FDASIA, joint solutions
should be sought with the Treasury Department.
The Treasury Department could leverage the
Increased Research Credit to provide tax incentives
to pharmaceutical companies to increase research
related to solving drug shortages by using the same
credit-calculation method as the Renewable Energy
Credit.
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